1869-24-5|2-(Trifluoromethyl)benzenesulfonamide| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1869-24-5 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1869-24-5 ]

CAS No. :	1869-24-5
Formula :	C₇H₆F₃NO₂S
M.W :	225.19
SMILES Code :	O=S(C1=CC=CC=C1C(F)(F)F)(N)=O
MDL No. :	MFCD00042420
InChI Key :	AFFPZJFLSDVZBV-UHFFFAOYSA-N
Pubchem ID :	2778018

Safety of [ 1869-24-5 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 1869-24-5 ] Show Less

Physicochemical Properties

Num. heavy atoms	14
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	2
Num. H-bond acceptors	6.0
Num. H-bond donors	1.0
Molar Refractivity	42.44
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	68.54 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.09
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.36
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.59
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.4
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.03
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.69

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.28
Solubility	1.19 mg/ml ; 0.00527 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.4
Solubility	0.893 mg/ml ; 0.00396 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.86
Solubility	0.312 mg/ml ; 0.00139 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.71 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.83

Application In Synthesis of [ 1869-24-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1869-24-5 ]

[ 1869-24-5 ] Synthesis Path-Downstream 1~35

1
[ 1869-24-5 ]
[ 122-51-0 ]
[ 727-43-5 ]

References: [1]Journal of Organic Chemistry,1961,vol. 26,p. 4315 - 4325.

2
[ 1869-24-5 ]
[ 10191-60-3 ]
[ 104667-64-3 ]

References: [1]Journal of Organic Chemistry,1988,vol. 53,p. 3120 - 3122.

3
[ 1869-24-5 ]
[ 65-85-0 ]
N-Benzoyl-2-trifluoromethyl-benzenesulfonamide [ No CAS ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 5891 - 5894.

4
[ 2960-66-9 ]
[ 1869-24-5 ]
ethyl (E)-4-[(2-trifluoromethylphenylsulfonyl)imino]-2-butenoate [ No CAS ]

References: [1]Journal of the American Chemical Society,2006,vol. 128,p. 2587 - 2593.

5
[ 915701-01-8 ]
[ 1869-24-5 ]
2-trifluoromethyl-N-[1-(3-trifluoromethyl-benzyl)-1H-indole-2-carbonyl]-benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2006,vol. 16,p. 5659 - 5663.

6
[ 1869-24-5 ]
2-((S)-2-Oxo-pyrrolidin-3-yloxy)-1-(2-trifluoromethyl-benzenesulfonyl)-1,2,3,4-tetrahydro-pyridine-4-carboxylic acid ethyl ester [ No CAS ]

References: [1]Journal of the American Chemical Society,2006,vol. 128,p. 2587 - 2593.

7
[ 1869-24-5 ]
[ 104667-73-4 ]

References: [1]Journal of Organic Chemistry,1988,vol. 53,p. 3120 - 3122.

8
[ 204378-36-9 ]
[ 1869-24-5 ]
[ 204378-14-3 ]

Yield	Reaction Conditions	Operation in experiment
83.7%		Synthesis Example 5 Synthesis of N-[(2-Trifluoromethylphenyl)sulfonyl]-5-methoxy-2-pyridinecarboxamide [Compound (I-54)] Using <strong>[1869-24-5]2-trifluoromethylbenzenesulfonamide</strong> [Compound (III-1)] (0.197 g, 0.87 mmol) and 5-methoxypicolinic acid phenyl ester [Compound (IV-54)] (0.2 g, 0.87 mmol), the Compound (I-54) was synthesised according to the process of Synthesis Example 1. White solid, yield: 0.262 g, percent yield: 83.7%, m.p.: 153-156 C. IR KBr cm-1: 3340, 1722, 1587, 1422, 1398, 1359, 1311, 1272, 1188, 1149, 588, 561. 1H-NMR (60 MHz, CDCl3, delta): 3.80 (3H, s, OCH3), 7.16 (1H, dd, J=3 Hz, 9 Hz, pyridine ring H), 7.46-7.80 (3H, m, aromatic ring H), 7.9 (1H, d, J=9 Hz, pyridine ring H), 8.13 (1H, d, J=3 Hz, pyridine ring H), 8.23-8.66 (1H, m, aromatic ring H), NH indistinctness.

References: [1]Patent: US6610853,2003,B1 .

9
[ 776-04-5 ]
[ 1869-24-5 ]

Yield	Reaction Conditions	Operation in experiment
95.6%		Synthesis Example 27 Synthesis of 2-Trifluoromethylbenzenesulfonamide [Compound (III-1)] Using 2-trifluoromethylbenzenesulfonyl chloride [Compound (XXII-1)] (5 g, 0.0204 mol), the Compound (III-1) was synthesised according to the process of Synthesis Example 26. White solid, m.p.: 186-187 C., yield: 4.4 g, percent yield: 95.6%. IR KBr cm-1: 3394, 3274, 1347, 1161, 1140. 1H-NMR (60 MHz, d6-DMSO, delta): 7.4-7.9 (5H, m, aromatic ring H*3, NH2), 7.9-8.4 (1H, m, aromatic ring H).
89%		Intermediate 1 : 2-(trifluoiOmethyl)benzenesulfonamide (cf. Scheme 3, compound XXI)To a solution of 2-(trifluoromethyl)benzenesulfonyl chloride (5g; 20.44 mmol; 1.00 eq.) in anhydrous THF (5.00 ml) was added a solution of 71 ml Ammonia in Ethanol 2M under nitrogen at room temperature. The reaction mixture was shaken for 2Oh at room temperature. The solvent was evaporated and the residue redissolved in EtOAc(15OmL) and then washed with NH4Cl saturated aqueous solution (5OmL) and brine (5OmL). The organic layer was dried over MgSO4, filtered and the solvent evaporated to give the pure 2- (trifluoromethyl)benzenesulfonamide as a yellowish solid (4.6g, 89% yield, 98.6% HPLC purity). This compound was utilized as such for the next reaction.IH NMR (300MHz, CDCl3); 5.0 (m, 2H), 7.6 (m, 2H), 7.8 (m, IH), 8.3 (m, IH). MS(ESr): 224.1.
	With ammonium hydroxide; In acetonitrile; at 0 - 20℃; for 1h;Inert atmosphere;	General procedure: In a 50 ml RB flask, sulfonyl chloride (500 mg) was taken in acetonitrile (5 ml) and the solution was cooled to 0 deg. Cel. To this aqueous ammonia solution (1.5 ml) was added dropwise. RM was then stirred at RT for 1 hr. RM was evaporated to dryness and the residue was then trichirated with minimum water and suspension was filtered and solid was dried to get the sulfonamide as solid.

References: [1]Patent: US6610853,2003,B1 .
[2]Patent: WO2006/111560,2006,A2 .Location in patent: Page/Page column 48.
[3]Bioorganic and Medicinal Chemistry Letters,2014,vol. 24,p. 2222 - 2225.

10
4-methyl-5-methylthio-2-phenoxythiocarbonyl-2,4-dihydro-3H-1,2,4-triazol-3-one [ No CAS ]
[ 1869-24-5 ]
[ 6674-22-2 ]
4-methyl-5-methylthio-2-(2-trifluoromethyl-phenylsulphonyl-aminothiocarbonyl)-2,4-dihydro-3H-1,2,4-triazol-3-one [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In dichloromethane; water; acetonitrile;	STR30 (by process (b)) At 20 C., 28.1 g (0.125 mol) of <strong>[1869-24-5]2-trifluoromethyl-benzenesulphonamide</strong> and a solution of 19 g of 1,8-diazabicyclo-[5.4.0]-undec-7-ene (DBU) in 50 ml of acetonitrile are added in succession to a solution of 28.1 g (0.10 mol) of 4-methyl-5-methylthio-2-phenoxythiocarbonyl-2,4-dihydro-3H-1,2,4-triazol-3-one in 300 ml of acetonitrile. The reaction mixture is stirred at 20 C. until a clear solution is obtained. The solution is then concentrated under water pump vacuum and the residue is admixed with water and methylene chloride (300 ml each) and acidified with 2N hydrochloric acid. The organic phase is separated off, the aqueous phase is extracted once more with 100 ml of methylene chloride and the combined organic phases are dried with magnesium sulphate and filtered. The filtrate is concentrated under a water pump vacuum and the residue is crystallized from isopropanol. 29.6 g (72% of theory) of 4-methyl-5-methylthio-2-(2-trifluoromethyl-phenylsulphonyl-aminothiocarbonyl)-2,4-dihydro-3H-1,2,4-triazol-3-one of melting point 154 C. are obtained. By the methods of Examples 1, 2 and 3 and in accordance with the general description of the preparation processes according to the invention, it is also possible to prepare, for example, the compounds of the formula (I) listed in Table 1 below. STR31

References: [1]Patent: US5972844,1999,A .

11
[ 1869-24-5 ]
[ 598-21-0 ]
[ 1048660-71-4 ]

References: [1]Journal of Medicinal Chemistry,2008,vol. 51,p. 4708 - 4714.

12
[ 938-16-9 ]
[ 1869-24-5 ]
[ 1263313-47-8 ]

References: [1]Journal of the American Chemical Society,2011,vol. 133,p. 1466 - 1474.

13
[ 1869-24-5 ]
[ 1152875-12-1 ]

References: [1]Journal of Organic Chemistry,2014,vol. 79,p. 4826 - 4831.

14
4-(cyclopropylcarbamoyl)benzoic acid [ No CAS ]
[ 1869-24-5 ]
N1-cyclopropyl-N4-(2-(trifluoromethyl)phenylsulfonyl)terephthalamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
70%	With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In acetonitrile; at 20℃; for 24h;	General procedure: To a stirred solution of 3I-3III (10 mmol) and Et3N (12 mmol) in anhydrous acetonitrile was added sulfamide (4a-i and 5, 10 mmol) followed by addition EDCI (12 mmol) and DMAP (12 mmol). The mixture was stirred at r.t. for 24 h. The reaction mixture was concentrated, and the residue was dissolved in dichloromethane. The organic layer was washed with 1N HCl and water for 3 times respectively, dried over anhydrous Na2SO4 and evaporated in vacuum. The residue was subjected to silica gel chromatography or crystallization.

References: [1]Bioorganic and Medicinal Chemistry Letters,2015,vol. 25,p. 791 - 794.

15
[ 1869-24-5 ]
2-trifluoromethylbenzenesulfonamide-6-d1 [ No CAS ]

References: [1]ACS Catalysis,2015,vol. 5,p. 402 - 410.

16
[ 5944-41-2 ]
[ 1869-24-5 ]
N-(2-methyl-2-(pyridin-2-yl)propyl)-2-(trifluoromethyl)benzenesulfonamide [ No CAS ]

References: [1]Angewandte Chemie - International Edition,2015,vol. 54,p. 9404 - 9408.
Angew. Chem.,2015,vol. 127,p. 9536 - 9540,5.

17
[ 611-32-5 ]
[ 1869-24-5 ]
N-(quinolin-8-ylmethyl)-2-(trifluoromethyl)benzenesulfonamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
66%	With silver hexafluoroantimonate; dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer; [bis(acetoxy)iodo]benzene; sodium acetate; In dichloromethane; at 20℃; for 48h;Inert atmosphere; Schlenk technique;	General procedure: A Schlenk tube with a magnetic stir bar was charged with [RhCp*Cl2]2 (7.8 mg, 12.5 mumol), AgSbF6 (17.2 mg, 50 mumol), PhI(OAc)2 (120.4 mg, 0.375 mmol), NaOAc (6.2mg, 75 mumol), 8-methylquinoline derivative 1 (0.50 mmol), amide 2 (0.25 mmol), and DCM (1.0 mL) under an N2 atmosphere. The resulting mixture was stirred at room temperature for 48 h and then diluted with 3 mL of dichloromethane. The solution was filtered through a celite pad and washed with 10-20 mL of dichloromethane. The filtrate was concentrated and the residue was purified by column chromatography on silica gel to provide the desired product.

References: [1]Chemistry Letters,2015,vol. 44,p. 1685 - 1687.

18
[ 1869-24-5 ]
[ 68790-38-5 ]
tert-butyl(2-(((2-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)phenyl)carbamate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
19%		General procedure: All solid chemicals used were dried in vacuum over P2O5 overnight.The acid derivative and CDI were dissolved in dry THF underN2 atmosphere and the mixture was allowed to stir at 66-68 C for2 h. The sulfonamide and DBU dissolved in THF were added to thereaction mixture and stirring was continued at room temperature(4 h-overnight).Method B1: The solvent was removed in vacuo, water was addedand pH was adjusted to 2 by addition of 1 M HCl aq. The aqueousphase was extracted with EtOAc (2 40 ml), dried with MgSO4, filteredand evaporated in vacuo. For most of the compounds, a silicagel column was first run, followed by purification on aluminumoxide.

References: [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 2603 - 2620.

19
[ 1869-24-5 ]
2-(2-(3-(3-(tert-butyl)ureido)-5-chloro-6-(2-cyclohexylethyl)-2-oxopyrazin-1(2H)-yl)acetamido)-N-((2-(trifluoromethyl)phenyl)sulfonyl)benzamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 2603 - 2620.

20
[ 1869-24-5 ]
C₁₄H₁₁F₃N₂O₃S*ClH [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry,2016,vol. 24,p. 2603 - 2620.

21
[ 1869-24-5 ]
[ 14790-72-8 ]
(4E,7E)-1,5,9,9-tetramethyl-12-((2-(trifluoromethyl)phenyl)sulfonyl)-12-azabicyclo[9.1.0]dodeca-4,7-dien-6-one [ No CAS ]

References: [1]European Journal of Organic Chemistry,2017,vol. 2017,p. 3072 - 3077.

22
[ 627-27-0 ]
[ 1869-24-5 ]
2-(1,1-difluoro-5-hydroxypentyl)benzenesulfonamide [ No CAS ]

References: [1]Journal of the American Chemical Society,2018,vol. 140,p. 163 - 166.

23
[ 13333-97-6 ]
[ 1869-24-5 ]

References: [1]Organic Letters,2018,vol. 20,p. 2599 - 2602.

24
[ 1869-24-5 ]
[ 24195-03-7 ]
methyl 2-(((2-(trifluoromethyl)phenyl)sulfonyl)carbamoyl)isonicotinate [ No CAS ]

References: [1]Chemistry - An Asian Journal,2018,vol. 13,p. 2854 - 2867.

25
[ 67-56-1 ]
[ 1869-24-5 ]
[ 4105-21-9 ]
N-((2-phenylimidazo[1,2-a]pyridin-3-yl)methyl)-2-(trifluoromethyl)benzenesulfonamide [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
84%	With potassium permanganate; di-tert-butyl peroxide; sodium t-butanolate; at 130℃; for 8h;	The preparation method comprises the following steps: adding 0.1 mmol of 2-phenylimidazo[1,2-a]pyridine compound to a 35 mL high pressure tube under an air atmosphere.0.2 mmol of <strong>[1869-24-5]2-(trifluoromethyl)benzenesulfonamide</strong>,0.2 mmol of di-tert-butyl peroxide, 0.1 mmolPotassium permanganate, 0.1 mmol of sodium t-butoxide, hexafluoroisopropanol and methanol (volume ratio 1:9) 2 mL, reacted at 130 C for 8 hours;After completion, chromatographic separation (silica gel 200-300 mesh, eluent: ethyl acetate / petroleum ether gradient elution, ratio from 0/100 to100/0), dried to a yellow solid, yield 84%.

References: [1]Organic and Biomolecular Chemistry,2019,vol. 17,p. 4869 - 4878.
[2]Patent: CN109824665,2019,A .Location in patent: Paragraph 0088-0091.

26
[ 1869-24-5 ]
N-(5-(tert-butyl)isoxazol-3-yl)-N-methyl-3-phenylpropiolamide [ No CAS ]
N-((E)-(2-((Z)-2-hydroxy-3,3-dimethylbut-1-en-1-yl)-1-methyl-5-oxo-1,5-dihydro-4H-imidazol-4-ylidene)(phenyl)methyl)-2-(trifluoromethyl)benzenesulfonamide [ No CAS ]

References: [1]Organic Letters,2019,vol. 21,p. 3946 - 3949.

27
[ 7342-82-7 ]
[ 1869-24-5 ]
N-(benzo[b]thiophen-3-yl)-2-(trifluoromethyl)benzenesulfonamide [ No CAS ]